a National Technical Advisory Group on Immunization Secretariat , National Institute of Health and Family Welfare , New Delhi , India.
d Former Immunization Technical Support Unit , Public Health Foundation of India , New Delhi , India.
Expert Rev Vaccines. 2018 Jun;17(6):555-562. doi: 10.1080/14760584.2018.1484285. Epub 2018 Jun 11.
India has implemented the World Health Organization's revised Causality Assessment Protocol for adverse events following immunization (AEFI). We describe the number and types of serious/severe AEFIs, including deaths.
Analysis of causality classification of reported serious/severe AEFIs from 1 January 2012 to 7 January 2016 was done. Classification includes (A) consistent with causal association to immunization; (B) indeterminate; (C) coincidental association; or (D) unclassifiable. We present descriptive statistics across each category.
Analysis of causality assessment completed for 1037 reports of serious AEFIs: 499 (48%) were causally associated, 84 (8%) were indeterminate, 323 (31%) were coincidental, and 131 (13%) were unclassifiable. Of the 499 reports in the A category, the events were causally linked to vaccine product for 189 (18%), to immunization error for 135 (13%), and to immunization anxiety for 175 (17%). Among 279 reported deaths, more than half (55%; n = 153) were coincidental events and 37% were unclassifiable.
Causality assessment of AEFI cases is an important component of vaccination programs and post-marketing surveillance of vaccines. Field reporting and investigation of AEFIs can be improved for many severe or serious reports, most of which are not causally linked to the vaccination program.
印度已实施世界卫生组织修订后的疫苗不良反应(AEFI)因果关系评估协议。我们描述了包括死亡在内的严重/严重 AEFI 的数量和类型。
对 2012 年 1 月 1 日至 2016 年 1 月 7 日报告的严重/严重 AEFI 的因果分类进行了分析。分类包括(A)与免疫接种有因果关系;(B)不确定;(C)巧合关联;或(D)无法分类。我们在每个类别中呈现了描述性统计数据。
对 1037 份严重 AEFI 报告的因果评估分析完成:499 份(48%)与因果关系相关,84 份(8%)不确定,323 份(31%)巧合,131 份(13%)无法分类。在 A 类报告的 499 份报告中,189 份(18%)与疫苗产品相关,135 份(13%)与免疫错误相关,175 份(17%)与免疫焦虑相关。在 279 例报告死亡中,超过一半(55%;n=153)是巧合事件,37%无法分类。
AEFI 病例的因果评估是疫苗接种计划和疫苗上市后监测的重要组成部分。可以改进许多严重或严重报告的现场报告和调查,其中大多数与疫苗接种计划没有因果关系。